Budesonide fails to outperform placebo in asthma trial

02/23/2009 | Boston Globe (tiered subscription model), The

A Phase III trial showed that unit dose budesonide was no better than placebo in improving asthma symptoms in children ages 1 to 8 years. The study investigated the efficacy of the drug in 0.25-mg and 0.135-mg doses when administered twice a day for 12 weeks. Budesonide co-maker AstraZeneca said it will coordinate with partner MAP Pharmaceuticals to review the results and discuss the next steps.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations